Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Humanized CD19 CAR-T in R/R B-ALL and B-NHL
NCT04532268Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Aug 2020
- Primary completion
- Aug 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial in B cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma, sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Incidence of treatment-emergent adverse events at 2 years. Started Aug 2020; status: recruiting.
02
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04532268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04532268.